Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.

@article{Minematsu2010CharacterizationOH,
  title={Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.},
  author={Tsuyoshi Minematsu and Megumi Iwai and Ken-Ichi Umehara and Takashi Usui and Hidetaka Kamimura},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2010},
  volume={38 1},
  pages={
          1-4
        }
}
1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide) is a novel small-molecule survivin suppressant that induces the down-regulation of survivin and exhibits potent antitumor activity in nude mice bearing human hormone refractory prostate carcinoma cell line PC-3. Although YM155, which has a cationic moiety in its structure, is influxed into its pharmacologically effective site (cancer cells) and one of its eliminating… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Metabolism of YM155 monobromide, a novel survivin suppressant: in vitro species comparison and identification of metabolites in rats

  • K Sohda, K Suzuki, +5 authors H Kamimura
  • Drug Metab Rev
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…